Galecto links blood cancer prospect to reduced fibrosis in early data drop

Galecto has linked its myelofibrosis candidate GB2064 to reduced collagen fibrosis in a small clinical trial, offering early validation of the ability of the LOXL2 inhibitor to act on a variable that affects outcomes.